Abstract
Adipokines are proteins produced by white adipose tissue, which is an active secretory organ. Regulation of immune and inflammatory responses is among the multiple physiological processes involving adipokines. Leptin, adiponectin and resistin are the most extensively studied adipokines. Leptin may promote inflammation by inducing Th1 phenotype development, whereas adiponectin may combat inflammation by reducing the production of pro-inflammatory cytokines. Resistin belongs to a family of proteins found in foci of inflammation, where they contribute to the inflammatory response. All three adipokines have been detected in synovial fluid from joints affected with the inflammatory disease rheumatoid arthritis (RA) or the degenerative disease osteoarthritis (OA). Recent evidence points to involvement of leptin in RA and OA and indicates that adiponectin and/or resistin mediate inflammation in arthritis. Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases.
Keywords: Adipokines, leptin, adiponectin, resistin, rheumatoid arthritis, osteoarthritis
Current Medicinal Chemistry
Title: The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases
Volume: 14 Issue: 10
Author(s): Eric Toussirot, Gerald Streit and Daniel Wendling
Affiliation:
Keywords: Adipokines, leptin, adiponectin, resistin, rheumatoid arthritis, osteoarthritis
Abstract: Adipokines are proteins produced by white adipose tissue, which is an active secretory organ. Regulation of immune and inflammatory responses is among the multiple physiological processes involving adipokines. Leptin, adiponectin and resistin are the most extensively studied adipokines. Leptin may promote inflammation by inducing Th1 phenotype development, whereas adiponectin may combat inflammation by reducing the production of pro-inflammatory cytokines. Resistin belongs to a family of proteins found in foci of inflammation, where they contribute to the inflammatory response. All three adipokines have been detected in synovial fluid from joints affected with the inflammatory disease rheumatoid arthritis (RA) or the degenerative disease osteoarthritis (OA). Recent evidence points to involvement of leptin in RA and OA and indicates that adiponectin and/or resistin mediate inflammation in arthritis. Thus, fat tissue is an active organ whose products contribute to inflammatory and degenerative processes underlying common joint diseases.
Export Options
About this article
Cite this article as:
Toussirot Eric, Streit Gerald and Wendling Daniel, The Contribution of Adipose Tissue and Adipokines to Inflammation in Joint Diseases, Current Medicinal Chemistry 2007; 14 (10) . https://dx.doi.org/10.2174/092986707780362826
DOI https://dx.doi.org/10.2174/092986707780362826 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
Current Cancer Therapy Reviews Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Targeting Complement in Rheumatoid Arthritis
Current Rheumatology Reviews Hypoxia Upregulates MAPK<sup>p38</sup>/MAPK<sup>ERK</sup> Phosphorylation In Vitro: Neuroimmunological Differential Time-Dependent Expression of MAPKs
Protein & Peptide Letters Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Preparation and Surface Modification of Polymeric Nanoparticles for Drug Delivery: State of the Art
Recent Patents on Drug Delivery & Formulation Editorial [ Hot Topic:Immunomodulation in Helminth Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets Introduction from Editor-in-Chief
Current Rheumatology Reviews Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy